SOLV · 10-Q · 2026Q2 · Full report
Acquisition / Partnership / Divestiture
Solventum Corp · 2026-08-05 · Importance 47 · Surprise 60 · In source text
On August 5, 2026, Solventum announced its intention to pursue a separation of the Health Information Systems business as part of portfolio optimization. The company will evaluate multiple separation pathways intended to maximize shareholder value, accelerate innovation, and enhance growth opportunities for both businesses. Separately, Solventum completed the sale of its Purification and Filtration business to Thermo Fisher Scientific on September 1, 2025, receiving approximately $4 billion in cash consideration. The retained Water Business is reported within All Other, while lost Purification and Filtration sales reduced reported company growth by 8.3% in the second quarter and 8.0% in the first six months of 2026.
Key facts
- On September 1, 2025, Solventum completed the sale of its Purification and Filtration business to Thermo Fisher Scientific Inc., and the cash consideration paid at closing was approximately $4 billion. source
- Solventum announced its intention to pursue a separation of its Health Information Systems business on August 5, 2026. source
- In December 2025, the Company acquired Acera Surgical (Acera); the contingent milestone payment upon achievement by December 31, 2030 is $__ million and the fair value of the future milestone payment was $__ million at December 31, 2025 (amounts redacted in filing). source
- On September 1, 2025, Solventum completed the sale of its Purification and Filtration business to Thermo Fisher Scientific, Inc. source
- Solventum is conducting a review of strategic alternatives for its health information systems business, including uncertainty as to the timing of the review and the ability to execute on material aspects and achieve any anticipated potential benefits. source
- The company identifies the risk that any failure by 3M to perform any of its obligations under the various separation agreements in connection with the Spin-Off could have adverse effects. source
- Acera purchase price allocations are preliminary as of June 30, 2026 with final estimates expected to be completed by the end of 2026; during the six months ended June 30, 2026 the Company recorded adjustments to the purchase price allocation of $__ million, primarily related to deferred taxes (amount redacted). source
- In connection with the Purification and Filtration sale, the Company entered into transition service agreements to provide support services for a period of up to __ months from closing (term redacted), and recognized an unfavorable contract liability of $__ million (amount redacted). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | unclear | probable | — | Solventum announced its intention to pursue a separation of its Health Information Systems business on August 5, 2026. |
| liability | negative | contingent | — | In December 2025, the Company acquired Acera Surgical (Acera); the contingent milestone payment upon achievement by December 31, 2030 is… |
| assets | unclear | contingent | — | Solventum is conducting a review of strategic alternatives for its health information systems business, including uncertainty as to the… |
| liability | negative | contingent | — | The company identifies the risk that any failure by 3M to perform any of its obligations under the various separation agreements in… |